TrialOpen Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Trial details
- Registry ID
- NCT04804605
- Phase
- Phase 3
Drug research
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Roflumilast
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic DermatitisNCT04804605 | ARQT | Phase 3 | Completed | 2024-05-28Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |